Does the media refer more to OMCL or AMN?

In the previous week, Omnicell had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 11 mentions for Omnicell and 5 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 1.02 beat AMN Healthcare Services' score of 0.83 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to OMCL or WST?

In the previous week, West Pharmaceutical Services had 15 more articles in the media than Omnicell. MarketBeat recorded 26 mentions for West Pharmaceutical Services and 11 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.63 beat Omnicell's score of 1.02 indicating that West Pharmaceutical Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive West Pharmaceutical Services 24 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, TFX or OMCL?

Omnicell has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 2.93 -$905.64M -$23.29 N/A Omnicell $1.18B 1.28 $2.05M $0.84 39.84

Is TFX or OMCL more profitable?

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% Omnicell 3.13% 5.66% 3.57%

Does the media favor TFX or OMCL?

In the previous week, Teleflex had 2 more articles in the media than Omnicell. MarketBeat recorded 13 mentions for Teleflex and 11 mentions for Omnicell. Omnicell's average media sentiment score of 1.02 beat Teleflex's score of 0.74 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MMED or OMCL?

In the previous week, Omnicell had 4 more articles in the media than MiniMed Group. MarketBeat recorded 11 mentions for Omnicell and 7 mentions for MiniMed Group. Omnicell's average media sentiment score of 1.02 beat MiniMed Group's score of 0.89 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, OMCL or LIVN?

Omnicell has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omnicell $1.18B 1.28 $2.05M $0.84 39.84 LivaNova $1.47B 2.98 -$242.47M $3.38 23.53

Is OMCL or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to Omnicell's net margin of 3.13%. LivaNova's return on equity of 16.35% beat Omnicell's return on equity. Company Net Margins Return on Equity Return on Assets Omnicell 3.13% 5.66% 3.57% LivaNova 12.82% 16.35% 7.76%

Does the media prefer OMCL or LIVN?

In the previous week, Omnicell had 7 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Omnicell and 4 mentions for LivaNova. Omnicell's average media sentiment score of 1.02 beat LivaNova's score of 0.41 indicating that Omnicell is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Omnicell (OMCL) Competitors

$33.50 +0.05 (+0.16%)

As of 01:12 PM Eastern

Compare

OMCL vs. AMN, WST, TFX, MMED, and LIVN

Should you buy Omnicell stock or one of its competitors? Omnicell's main competitors and comparable companies include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), Teleflex (TFX), MiniMed Group (MMED), and LivaNova (LIVN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Omnicell compare to AMN Healthcare Services?

Omnicell (NASDAQ:OMCL) and AMN Healthcare Services (NYSE:AMN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Omnicell had 6 more articles in the media than AMN Healthcare Services. MarketBeat recorded 11 mentions for Omnicell and 5 mentions for AMN Healthcare Services. Omnicell's average media sentiment score of 1.02 beat AMN Healthcare Services' score of 0.83 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Omnicell presently has a consensus price target of $57.86, indicating a potential upside of 72.89%. AMN Healthcare Services has a consensus price target of $31.43, indicating a potential downside of 9.47%. Given Omnicell's stronger consensus rating and higher possible upside, research analysts plainly believe Omnicell is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Omnicell has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Omnicell has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.28	$2.05M	$0.84	39.84
AMN Healthcare Services	$2.73B	0.49	-$95.70M	$2.68	12.95

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
AMN Healthcare Services	3.06%	19.92%	5.93%

Summary

Omnicell beats AMN Healthcare Services on 11 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

Omnicell (NASDAQ:OMCL) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

West Pharmaceutical Services has a net margin of 16.98% compared to Omnicell's net margin of 3.13%. West Pharmaceutical Services' return on equity of 20.11% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
West Pharmaceutical Services	16.98%	20.11%	14.83%

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.28	$2.05M	$0.84	39.84
West Pharmaceutical Services	$3.33B	7.40	$493.70M	$7.81	44.76

Omnicell has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, West Pharmaceutical Services had 15 more articles in the media than Omnicell. MarketBeat recorded 26 mentions for West Pharmaceutical Services and 11 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.63 beat Omnicell's score of 1.02 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
West Pharmaceutical Services	24 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Omnicell currently has a consensus price target of $57.86, suggesting a potential upside of 72.89%. West Pharmaceutical Services has a consensus price target of $368.08, suggesting a potential upside of 5.29%. Given Omnicell's higher probable upside, research analysts clearly believe Omnicell is more favorable than West Pharmaceutical Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
West Pharmaceutical Services	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

West Pharmaceutical Services beats Omnicell on 14 of the 17 factors compared between the two stocks.

How does Omnicell compare to Teleflex?

Teleflex (NYSE:TFX) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Omnicell has a net margin of 3.13% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
Omnicell	3.13%	5.66%	3.57%

In the previous week, Teleflex had 2 more articles in the media than Omnicell. MarketBeat recorded 13 mentions for Teleflex and 11 mentions for Omnicell. Omnicell's average media sentiment score of 1.02 beat Teleflex's score of 0.74 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teleflex currently has a consensus price target of $152.90, indicating a potential upside of 10.77%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 72.89%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Teleflex has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

95.6% of Teleflex shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.7% of Teleflex shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Omnicell has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.93	-$905.64M	-$23.29	N/A
Omnicell	$1.18B	1.28	$2.05M	$0.84	39.84

Summary

Omnicell beats Teleflex on 11 of the 17 factors compared between the two stocks.

How does Omnicell compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

In the previous week, Omnicell had 4 more articles in the media than MiniMed Group. MarketBeat recorded 11 mentions for Omnicell and 7 mentions for MiniMed Group. Omnicell's average media sentiment score of 1.02 beat MiniMed Group's score of 0.89 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiniMed Group presently has a consensus price target of $21.62, suggesting a potential upside of 10.64%. Omnicell has a consensus price target of $57.86, suggesting a potential upside of 72.89%. Given Omnicell's higher possible upside, analysts clearly believe Omnicell is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

97.7% of Omnicell shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Omnicell has a net margin of 3.13% compared to MiniMed Group's net margin of 0.00%. Omnicell's return on equity of 5.66% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Omnicell	3.13%	5.66%	3.57%

Omnicell has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A
Omnicell	$1.18B	1.28	$2.05M	$0.84	39.84

Summary

Omnicell beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

How does Omnicell compare to LivaNova?

Omnicell (NASDAQ:OMCL) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Omnicell currently has a consensus target price of $57.86, suggesting a potential upside of 72.89%. LivaNova has a consensus target price of $83.50, suggesting a potential upside of 4.99%. Given Omnicell's stronger consensus rating and higher possible upside, equities research analysts clearly believe Omnicell is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55

LivaNova has a net margin of 12.82% compared to Omnicell's net margin of 3.13%. LivaNova's return on equity of 16.35% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	3.13%	5.66%	3.57%
LivaNova	12.82%	16.35%	7.76%

In the previous week, Omnicell had 7 more articles in the media than LivaNova. MarketBeat recorded 11 mentions for Omnicell and 4 mentions for LivaNova. Omnicell's average media sentiment score of 1.02 beat LivaNova's score of 0.41 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	7 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omnicell has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.18B	1.28	$2.05M	$0.84	39.84
LivaNova	$1.47B	2.98	-$242.47M	$3.38	23.53

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Omnicell has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

Summary

Omnicell beats LivaNova on 10 of the 16 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.52B	$5.77B	$7.24B	$12.90B
Dividend Yield	N/A	1.75%	2.54%	11.02%
P/E Ratio	39.84	25.97	272.49	24.28
Price / Sales	1.28	69.54	606.96	79.45
Price / Cash	12.01	33.21	79.89	53.65
Price / Book	1.18	6.25	13.11	6.27
Net Income	$2.05M	$149.10M	$3.46B	$347.96M
7 Day Performance	-5.73%	1.04%	2.13%	1.56%
1 Month Performance	-19.34%	8.29%	8.29%	4.80%
1 Year Performance	0.71%	6.91%	26.58%	17.12%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	4.0156 of 5 stars	$33.50 +0.2%	$57.86 +72.7%	+2.2%	$1.52B	$1.18B	39.88	3,580	Analyst Forecast
AMN AMN Healthcare Services	2.0107 of 5 stars	$34.46 -0.1%	$31.43 -8.8%	+67.8%	$1.34B	$2.73B	12.86	2,664	Analyst Downgrade
WST West Pharmaceutical Services	4.0526 of 5 stars	$346.69 -0.8%	$368.08 +6.2%	+43.5%	$24.59B	$3.07B	44.39	10,800	News Coverage Positive News
TFX Teleflex	3.526 of 5 stars	$133.05 -3.0%	$151.80 +14.1%	+9.0%	$5.81B	$1.99B	N/A	15,500	Positive News Analyst Forecast Short Interest Increase
MMED MiniMed Group	2.3907 of 5 stars	$19.53 -3.1%	$21.62 +10.7%	N/A	$5.66B	$3.10B	N/A	2,800	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, TFX, MMED, and LIVN

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to Teleflex?

Summary

How does Omnicell compare to MiniMed Group?

Summary

How does Omnicell compare to LivaNova?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. AMN, WST, TFX, MMED, and LIVN

How does Omnicell compare to AMN Healthcare Services?

Does the media refer more to OMCL or AMN?

Do analysts prefer OMCL or AMN?

Which has more risk and volatility, OMCL or AMN?

Which has better valuation & earnings, OMCL or AMN?

Do insiders & institutionals believe in OMCL or AMN?

Is OMCL or AMN more profitable?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Is OMCL or WST more profitable?

Which has stronger valuation and earnings, OMCL or WST?

Which has more risk & volatility, OMCL or WST?

Does the media refer more to OMCL or WST?

Do insiders & institutionals have more ownership in OMCL or WST?

Do analysts rate OMCL or WST?

Summary

How does Omnicell compare to Teleflex?

Is TFX or OMCL more profitable?

Does the media favor TFX or OMCL?

Do analysts prefer TFX or OMCL?

Which has more risk and volatility, TFX or OMCL?

Do insiders & institutionals believe in TFX or OMCL?

Which has stronger earnings and valuation, TFX or OMCL?

Summary

How does Omnicell compare to MiniMed Group?

Does the media prefer MMED or OMCL?

Do analysts prefer MMED or OMCL?

Do insiders and institutionals have more ownership in MMED or OMCL?

Is MMED or OMCL more profitable?

Which has better earnings and valuation, MMED or OMCL?

Summary

How does Omnicell compare to LivaNova?

Do analysts rate OMCL or LIVN?

Is OMCL or LIVN more profitable?

Does the media prefer OMCL or LIVN?

Which has better earnings and valuation, OMCL or LIVN?

Do insiders & institutionals have more ownership in OMCL or LIVN?

Which has more volatility & risk, OMCL or LIVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools